These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24869939)

  • 1. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.
    Lu M; Xia L; Li Y; Wang X; Hoffman R
    Blood; 2014 Jul; 124(5):771-9. PubMed ID: 24869939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 at the crossroads of MPN treatment.
    Plo I
    Blood; 2014 Jul; 124(5):668-9. PubMed ID: 25082860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.
    Lu M; Wang X; Li Y; Tripodi J; Mosoyan G; Mascarenhas J; Kremyanskaya M; Najfeld V; Hoffman R
    Blood; 2012 Oct; 120(15):3098-105. PubMed ID: 22872685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
    Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW
    Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.
    Lu M; Wang J; Li Y; Berenzon D; Wang X; Mascarenhas J; Xu M; Hoffman R
    Blood; 2010 Nov; 116(20):4284-7. PubMed ID: 20625010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells.
    Wang X; Haylock D; Hu CS; Kowalczyk W; Jiang T; Qiu J; Mosoyan G; He W; Marshall N; Mascarenhas J; Tarasova A; Brody J; Winkler D; Hoffman R
    Blood; 2016 Jun; 127(26):3398-409. PubMed ID: 27114459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live and let (MPN cells) die!
    Cassinat B; Kiladjian JJ
    Blood; 2012 Oct; 120(15):2933-4. PubMed ID: 23065008
    [No Abstract]   [Full Text] [Related]  

  • 8. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice.
    Ishii T; Zhao Y; Sozer S; Shi J; Zhang W; Hoffman R; Xu M
    Exp Hematol; 2007 Nov; 35(11):1633-40. PubMed ID: 17764815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.
    Lu M; Zhang W; Li Y; Berenzon D; Wang X; Wang J; Mascarenhas J; Xu M; Hoffman R
    Exp Hematol; 2010 Jun; 38(6):472-80. PubMed ID: 20303384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
    Wang X; Zhang W; Tripodi J; Lu M; Xu M; Najfeld V; Li Y; Hoffman R
    Blood; 2010 Dec; 116(26):5972-82. PubMed ID: 20858855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
    Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
    Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.
    James C; Mazurier F; Dupont S; Chaligne R; Lamrissi-Garcia I; Tulliez M; Lippert E; Mahon FX; Pasquet JM; Etienne G; Delhommeau F; Giraudier S; Vainchenker W; de Verneuil H
    Blood; 2008 Sep; 112(6):2429-38. PubMed ID: 18612101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.
    Tashi T; Swierczek S; Kim SJ; Salama ME; Song J; Heikal N; King KY; Hickman K; Litton S; Prchal JT
    Leukemia; 2018 Aug; 32(8):1830-1833. PubMed ID: 29556018
    [No Abstract]   [Full Text] [Related]  

  • 14. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.
    Bjørn ME; Hasselbalch HC
    Expert Rev Hematol; 2017 May; 10(5):393-404. PubMed ID: 28402197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
    Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
    Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
    Wang J; Ishii T; Zhang W; Sozer S; Dai Y; Mascarenhas J; Najfeld V; Zhao ZJ; Hoffman R; Wisch N; Xu M
    Leukemia; 2009 Sep; 23(9):1577-86. PubMed ID: 19387466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.
    Wang X; LeBlanc A; Gruenstein S; Xu M; Mascarenhas J; Panzera B; Wisch N; Parker C; Goldberg JD; Prchal J; Hoffman R; Najfeld V
    Exp Hematol; 2009 Oct; 37(10):1194-200. PubMed ID: 19615425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
    Mullally A; Lane SW; Ball B; Megerdichian C; Okabe R; Al-Shahrour F; Paktinat M; Haydu JE; Housman E; Lord AM; Wernig G; Kharas MG; Mercher T; Kutok JL; Gilliland DG; Ebert BL
    Cancer Cell; 2010 Jun; 17(6):584-96. PubMed ID: 20541703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells.
    King KY; Matatall KA; Shen CC; Goodell MA; Swierczek SI; Prchal JT
    Exp Hematol; 2015 Oct; 43(10):912-918.e2. PubMed ID: 26072330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.